Charles River Laboratories International (CRL)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$1.56 (-0.77%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Charles River Laboratories International (CRL)
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Key Insights

Critical company metrics and information
  • Share Price

    $199.97
  • Market Cap

    $10.23 Billion
  • Total Outstanding Shares

    51.14 Million Shares
  • Total Employees

    21,400
  • Dividend

    No dividend
  • IPO Date

    June 23, 2000
  • SIC Description

    Services-commercial Physical & Biological Research
  • Homepage

    https://www.criver.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

September 29, 2023 to September 28, 2024
MetricValue
Net Cash Flow, Continuing$37.33 Million
Net Cash Flow From Investing Activities$-407.35 Million
Net Cash Flow$46.02 Million
Net Cash Flow From Operating Activities$796.16 Million
Net Cash Flow From Financing Activities$-351.48 Million
Net Cash Flow From Operating Activities, Continuing$796.16 Million
Net Cash Flow From Investing Activities, Continuing$-407.35 Million
Exchange Gains/Losses$8.70 Million
Net Cash Flow From Financing Activities, Continuing$-351.48 Million

Income Statement

September 29, 2023 to September 28, 2024
MetricValue
Net Income/Loss$427.99 Million
Benefits Costs and Expenses$3.55 Billion
Revenues$4.06 Billion
Operating Income/Loss$527.96 Million
Preferred Stock Dividends And Other Adjustments$10.70 Million
Other Operating Expenses$2.76 Billion
Net Income/Loss Attributable To Noncontrolling Interest$4.21 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$10.70 Million
Costs And Expenses$3.57 Billion
Selling, General, and Administrative Expenses$752.44 Million
Income/Loss From Continuing Operations Before Tax$512.79 Million
Diluted Average Shares$103.35 Million
Income/Loss From Continuing Operations After Tax$427.99 Million
Basic Average Shares$154.41 Million
Net Income/Loss Attributable To Parent$423.78 Million
Net Income/Loss Available To Common Stockholders, Basic$413.08 Million
Diluted Earnings Per Share$8.01
Income Tax Expense/Benefit$90.62 Million
Operating Expenses$3.51 Billion
Basic Earnings Per Share$8.04

Balance Sheet

September 29, 2023 to September 28, 2024
MetricValue
Redeemable Noncontrolling Interest$40.59 Million
Other Current Liabilities$665.18 Million
Wages$211.08 Million
Noncurrent Liabilities$3.16 Billion
Current Assets$1.49 Billion
Liabilities$4.18 Billion
Other Current Assets$1.07 Billion
Assets$8.00 Billion
Equity Attributable To Parent$3.78 Billion
Liabilities And Equity$8.00 Billion
Inventory$336.20 Million
Noncurrent Assets$6.51 Billion
Temporary Equity$40.59 Million
Equity Attributable To Noncontrolling Interest$4.85 Million
Equity$3.79 Billion
Prepaid Expenses$92.63 Million
Current Liabilities$1.01 Billion
Accounts Payable$135.96 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.